Autor según el artículo: Ettcheto, Miren; Olloquequi, Jordi; Sanchez-Lopez, Elena; Busquets, Oriol; Cano, Amanda; Regina Manzine, Patricia; Beas-Zarate, Carlos; Castro-Torres, Ruben D; Luisa Garcia, Maria; Bullo, Monica; Auladell, Carme; Folch, Jaume; Camins, Antoni
Departamento: Bioquímica i Biotecnologia
Autor/es de la URV: Bulló Bonet, Mònica / Folch Lopez, Jaume
Palabras clave: Sleep disturbance Risk factors Pharmacological-treatment Long-term use Insomnia Impairment Gabaergic deafferentation hypothesis Dementia Cognitive decline Cognition Clinical-practice guideline Benzodiazepines Amyloid-beta American academy Alzheimer's disease dementia cognition benzodiazepines alzheimer's disease
Resumen: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to their anxiolytic, hypnotic, and muscle relaxant properties. Yet, their chronic use is associated with cases of abuse, dependence, and relapse in many patients. Furthermore, elderly people are susceptible to alterations in pharmacodynamics, pharmacokinetics as well as to drug interaction due to polypharmacy. These situations increase the risk for the appearance of cognitive affectations and the development of pathologies like Alzheimer's disease (AD). In the present work, there is a summary of some clinical studies that have evaluated the effect of BZDs and Z-drugs in the adult population with and without AD, focusing on the relationship between their use and the loss of cognitive function. Additionally, there is an assessment of preclinical studies focused on finding molecular proof on the pathways by which these drugs could be involved in AD pathogenesis. Moreover, available data (1990-2019) on BZD and Z-drug use among elderly patients, with and without AD, was compiled in this work. Finally, the relationship between the use of BZD and Z-drugs for the treatment of insomnia and the appearance of AD biomarkers was analyzed. Results pointed to a vicious circle that would worsen the condition of patients over time. Likewise, it put into relevance the need for close monitoring of those patients using BZDs that also suffer from AD. Consequently, future studies should focus on optimizing strategies for insomnia treatment in the elderly by using other substances like melatonin agonists, which is described to have a much more significant safety profile.
Áreas temáticas: Saúde coletiva Química Psicología Nutrição Neurosciences Medicina veterinaria Medicina ii Medicina i Interdisciplinar Geriatrics & gerontology Engenharias iv Educação física Cognitive neuroscience Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade Aging
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 16634365
Direcció de correo del autor: monica.bullo@urv.cat jaume.folch@urv.cat
Identificador del autor: 0000-0002-0218-7046 0000-0002-5051-8858
Fecha de alta del registro: 2024-10-12
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2019.00344/full
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Frontiers In Aging Neuroscience. 11 (344): 344-
Referencia de l'ítem segons les normes APA: Ettcheto, Miren; Olloquequi, Jordi; Sanchez-Lopez, Elena; Busquets, Oriol; Cano, Amanda; Regina Manzine, Patricia; Beas-Zarate, Carlos; Castro-Torres, (2020). Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. Frontiers In Aging Neuroscience, 11(344), 344-. DOI: 10.3389/fnagi.2019.00344
DOI del artículo: 10.3389/fnagi.2019.00344
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2020
Tipo de publicación: Journal Publications